WEHI Special Centre for Biologic Therapies Seminar hosted by Associate Professor Jenny Vo

Colby Souders PhD

Chief Scientific Officer, Twist Biopharma Solutions

Rewriting the Paradigm of Biologic Drug Discovery Using AI/Machine Learning Methodologies

 

Davis Auditorium

Join via TEAMS

Including Q&A session

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma Solutions develops end-to-end antibody discovery platforms, including both (1) highly diverse synthetic naïve antibody phage display libraries, (2) in vivo animal immunization workflows (proprietary mouse, single B-cell cloning, llama VHH discovery).  In this talk, Dr. Colby Souders, CSO of Twist Biopharma Solutions, will discuss case studies highlighting the discovery and pre-clinical validation of antibody candidates using structure-guided de novo design and machine learning strategies. He will introduce our latest advancements in custom in vitro library design for phage and yeast display techniques.

Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at BrickBio, Abveris, Kanyos Bio and MassBiologics, while contributing to multiple candidates currently in the clinic. At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as developed related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby has served as Chief Scientific Officer at BrickBio to develop novel antibody drug conjugates and was CSO at Abveris prior to acquisition by Twist Bioscience. He now serves as the CSO of Twist Biopharma Solutions to guide the biologics discovery division of Twist Bioscience.

Colby Souders earned his PhD in Cell and Molecular Biology from Texas A&M and previously held positions at BrickBio, Abveris, MassBiologics and Kanyos Bio. At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as developed related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby has served as Chief Scientific Officer at BrickBio to develop novel antibody drug conjugates and was CSO at Abveris prior to acquisition by Twist Bioscience. He now serves as the CSO of Twist Biopharma to guide the biologics discovery division of Twist.

All welcome!